Zi‐Yang Shi

机构：Shanghai Jiao Tong University, Ruijin Hospital, Shanghai Institute of Hematology · ORCID：0000-0001-5535-5202

发表论文 13 篇 · 总被引 211 次 · h-index 6

代表论文

• Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma (2023 · Signal Transduction and Targeted Therapy · 被引 106)
• Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study (2022 · The Lancet Healthy Longevity · 被引 36)
• Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma (2024 · Blood Advances · 被引 25)
• Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma (2022 · Frontiers in Immunology · 被引 18)
• The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review (2022 · Clinical Lymphoma Myeloma & Leukemia · 被引 11)
• A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma (2025 · Blood · 被引 6)